Thymidylate synthase predictive power is overcome by irinotecan combination therapy with S-1 for gastric cancer

British Journal of Cancer

Volumn 91, Issue 7, 2004, Pages 1245-1250

  Ichikawa, W ^a   Takahashi, T ^a   Suto, K ^a   Yamashita, T ^b   Nihei, Z ^b   Shirota, Y ^b   Shimizu, M ^a   Sasaki, Y ^a   Hirayama, R ^a  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

^b Tojun Hospital   (Japan)

Author keywords

Dihydropyrimidine dehydrogenase; Gastric cancer; Irinotecan; S 1; Thymidylate synthase

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; DIHYDROPYRIMIDINE DEHYDROGENASE; IRINOTECAN; THYMIDYLATE SYNTHASE; ANTINEOPLASTIC ANTIMETABOLITE; OXONIC ACID; PYRIDINE DERIVATIVE; S 1 (COMBINATION); TEGAFUR;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA SYNTHESIS; DPD GENE; FEMALE; GENE; GENE EXPRESSION; HUMAN; MAJOR CLINICAL STUDY; MALE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; STOMACH CANCER; TS GENE; BIOSYNTHESIS; DRUG COMBINATION; ENZYMOLOGY; GENE EXPRESSION PROFILING; GENETICS; METASTASIS; MIDDLE AGED; PREDICTION AND FORECASTING; PROGNOSIS; STOMACH TUMOR; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; DIHYDROURACIL DEHYDROGENASE (NADP); DRUG COMBINATIONS; FEMALE; GENE EXPRESSION PROFILING; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; OXONIC ACID; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PYRIDINES; STOMACH NEOPLASMS; TEGAFUR; THYMIDYLATE SYNTHASE; TREATMENT OUTCOME;

EID: 6944226476     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6602139     Document Type: Article

References (32)

1. Ajani JA (2000) Standard chemotherapy for gastric carcinoma: is it a myth? J Clin Oncol 18: 4001-4003
2. Boku N, Chin K, Hosokawa K, Ohtsu A, Tajiri H, Yoshida S, Yamao T, Kondo H, Shirao K, Shimada Y, Saito D, Hasebe T, Mukai K, Seki S, Saito H, Johnston PG (1998) Biological markers as a predictor for response and prognosis of unresectable gastric cancer patients treated with 5-fluorouracil and cis-platinum. Clin Cancer Res 4: 1469-1474
3. Danenberg PV (2003) Molecular markers of chemotherapy resistance. In Colorectal Cancer Multimodality Management Saltz LB (ed) pp 621-633, Totowa, NJ: Human Press
4. Fujiwara H, Terashima M, Irinoda T, Takagane A, Abe K, Nakaya T, Yonezawa H, Oyama K, Takahashi M, Saito K, Takechi T, Fukushima M, Shirasaka T (2003) Superior antitumour activity of S-1 in tumours with a high dihydropyrimidine dehydrogenase activity. Eur J Cancer 39: 2387-2394
5. Futatsuki K, Wakui A, Nakao I, Sakata Y, Kambe M, Shimada Y, Yoshino M, Taguchi T, Ogawa N (1994) [Late phase II study of irinotecan hydrochloride (CPT- 11) in advanced gastric cancer. CPT-11 Gastrointestinal Cancer Study Group]. Jpn J Cancer Chemotherapy 21: 1033-1038
6. Hayward JL, Rubens RD, Carbone PP, Heuson JC, Kumaoka S, Segaloff A (1978) Assessment of response to therapy in advanced breast cancer. A project of the programme on clinical oncology of the International Union against Cancer, Geneva, Switzerland. Eur J Cancer 14: 1291-1292
7. Heggie GD, Sommadossi JP, Cross DS, Huster WJ, Diasio RB (1987) Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res 47: 2203-2206
8. Hsiang YH, Liu LF, Wall ME, Wani MC, Nicholas AW, Manikumar G, Kirschenbaum S, Silber R, Potmesil M (1989) DNA topoisomerase I-mediated DNA cleavage and cytotoxicity of camptothecin analogues. Cancer Res 49: 4385-4389
9. Ichikawa W, Takahashi T, Suto K, Nihei Z, Shirota Y, Shimizu M, Sasaki Y, Hirayama R. Thymidylate synthase and dihydropyrimidine dehydrogenase gene expression in relation to differentiation of gastric cancer. Int J Cancer in press
10. Ichikawa W, Uetake H, Nihei Z, Matsuo K, Fujita H, Yamada Y (1999) Topoisomerase-I (Topo-I) expression correlates to thymidylate synthase (TS) expression in colorectal cancer (CRC). Proc Am Soc Clin Oncol 18: 246a
11. Ichikawa W, Uetake H, Shirota Y, Yamada H, Nishi N, Nihei Z, Sugihara K, Hirayama R (2003) Combination of dihydropyrimidine dehydrogenase and thymidylate synthase gene expressions in primary tumors as predictive parameters for the efficacy of fluoropyrimidine-based chemotherapy for metastatic colorectal cancer. Clin Cancer Res 9: 786-791
12. Ishikawa Y, Kubota T, Otani Y, Watanabe M, Teramoto T, Kumai K, Kitajima M, Takechi T, Okabe H, Fukushima M (1999) Dihydropyrimidine dehydrogenase activity and messenger RNA level may be related to the antitumor effect of 5-fluorouracil on human tumor xenografts in nude mice. Clin Cancer Res 5: 883-889
13. Koizumi W, Kurihara M, Nakano S, Hasegawa K (2000) Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group. Oncology 58: 191-197
14. Kornmann M, Schwabe W, Sander S, Kron M, Strater J, Polat S, Kettner E, Weiser HF, Baumann W, Schramm H, Hausler P, Ott K, Behnke D, Staib L, Beger HG, Link KH (2003) Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression levels: predictors for survival in colorectal cancer patients receiving adjuvant 5-fluorouracil. Clin Cancer Res 9: 4116-4124
15. Langenbach RJ, Danenberg PV, Heidelberger C (1972) Thymidylate synthetase: mechanism of inhibition by 5-fluoro-2′-deoxyuridylate. Biochem Biophys Res Commun 48: 1565-1571
16. Lenz HJ, Leichman CG, Danenberg KD, Danenberg PV, Groshen S, Cohen H, Laine L, Crookes P, Silberman H, Baranda J, Garcia Y, Li J, Leichman L (1995) Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival. J Clin Oncol 14: 176-182
17. Lord RV, Salonga D, Danenberg KD, Peters JH, DeMeester TR, Park JM, Johansson J, Skinner KA, Chandrasoma P, DeMeester SR, Bremner CG, Tsai PI, Danenberg PV (2000) Telomerase reverse transcriptase expression is increased early in the Barrett's metaplasia, dysplasia, adenocarcinoma sequence. J Gastrointest Surg 4: 135-142
18. McLeod HL, Keith WN (1996) Variation in topoisomerase I gene copy number as a mechanism for intrinsic drug sensitivity. Br J Cancer 74: 508-512
19. Miyamoto S, Boku N, Ohtsu A, Yoshida S, Ochiai A, Okabe H, Fukushima M (2000) Clinical implications of immunoreactivity of thymidylate synthase and dihydropyrimidine dehydrogenase in gastric cancer treated with oral fluoropyrimidine (S-1). Study Group of S-1 for Gastric Cancer. Int J Oncol 17: 653-658
20. Nozawa H, Tsukui H, Nishida K, Yakumaru K, Nagawa H, Sekikawa T (2002) Dihydropyrimidine dehydrogenase expression in preoperative biopsy and surgically resected specimens of gastric carcinoma. Cancer Chemother Pharmacol 49: 267-273
21. Ohtsu A, Shimada Y, Shirao K, Boku N, Hyodo I, Saito H, Yamamichi N, Miyata Y, Ikeda N, Yamamoto S, Fukuda H, Yoshida S (2003) Randomized phase III trial of fluorouracil alone vs fluorouracil plus cisplatin vs uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205). J Clin Oncol 21: 54-59
22. Peters GJ, van der Wilt CL, van Triest B, Codacci-Pisanelli G, Johnston PG, van Groeningen CJ, Pinedo HM (1995) Thymidylate synthase and drug resistance. Eur J Cancer 31A: 1299-1305
23. Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y, Taguchi T (1998) Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 Mtegafur-0.4 Mgimestat-1 M otastat potassium) in advanced gastric cancer patients. Eur J Cancer 34: 1715-1720
24. Salonga D, Danenberg KD, Johnson M, Metzger R, Groshen S, Tsao-Wei DD, Lenz HJ, Leichman CG, Leichman L, Diasio RB, Danenberg PV (2000) Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 6: 1322-1327
25. Shirasaka T, Shimamato Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K, Fukushima M (1996) Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 7: 548-557
26. Takechi T, Fujioka A, Matsushima E, Fukushima M (2002) Enhancement of the antitumour activity of 5-fluorouracil (5-FU) by inhibiting dihydropyrimidine dehydrogenase activity (DPD) using 5-chloro-2,4-dihydroxypyridine (CDHP) in human tumour cells. Eur J Cancer 38: 1271-1277
27. Tatsumi K, Fukushima M, Shirasaka T, Fujii S (1987) Inhibitory effects of pyrimidine, barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extracts. Jpn J Cancer Res 78: 748-755
28. Vanhoefer U, Harstrick A, Achterrath W, Cao S, Seeber S, Rustum YM (2001) Irinotecan in the treatment of colorectal cancer: clinical overview. J Clin Oncol 19: 1501-1518
29. Yamada Y, Hamaguchi T, Goto M, Muro K, Matsumura Y, Shimada Y, Shirao K, Nagayama S (2003) Plasma concentrations of 5-fluorouracil and F-beta-alanine following oral administration of S-1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infusion of 5-fluorouracil. Br J Cancer 89: 816-820
30. Yamashita T, Ichikawa W, Nihei Z, Kojima K, Kawano T, Sugihara K (2003) A phase I study of S-1 and weekly CPT-11 for patients with advanced gastric cancer. Proc Am Soc Clin Oncol 22: 356
31. Yeh KH, Shun CT, Chen CL, Lin JT, Lee WJ, Lee PH, Chen YC, Cheng AL (1998) High expression of thymidylate synthase is associated with the drug resistance of gastric carcinoma to high dose 5-fluorouracil-based systemic chemotherapy. Cancer 82: 1626-1631
32. Zubrod C, Schneiderman M, Frei J (1960) Appraisal of methods for study of chemotherapy of cancer in man: comparative therapeutic trial of nitrogen mustard thiethylene thiophosphoramide. J Chron Dis 11: 7-33